Core Insights - Aethlon Medical, Inc. will release its financial results for the fiscal second quarter ended September 30, 2025, on November 12, 2025, at 4:15 p.m. ET [1] - A conference call will be held on the same day at 4:30 p.m. ET to discuss the financial results and recent corporate developments [2] - The Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation [4] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focusing on oncology and infectious diseases [6] - The Hemopurifier has received U.S. Food and Drug Breakthrough Device Designation for treating advanced or metastatic cancer and life-threatening viruses [5] Conference Call Details - Interested parties can register for the conference call online, and those without internet access can dial in using provided toll-free numbers [2][3] - A replay of the call will be available approximately one hour after the call ends, accessible through the company's website or via specific phone numbers [4]

Core Points - Aethlon Medical, Inc. announced a public offering of 5,000,000 shares of common stock and warrants to purchase an additional 5,000,000 shares at a price of $0.90 per share [1] - The gross proceeds from the offering are expected to be approximately $4.5 million, which will be used for general corporate purposes including clinical trial expenses and research and development [2] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier to address needs in oncology and infectious diseases [5]

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on May 13, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Name, address, including zip code, and telephone number, including area code, of agent for service) (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 25, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id ...

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 5, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide ...

Table of Contents Registration No. 333- As filed with the Securities and Exchange Commission on March 22, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 1155 ...